June 10th 2020, 7:56pm
The combination of nivolumab plus ipilimumab was found to induce a superior response rate and longer progression-free survival compared with nivolumab alone in patients with persistent or recurrent epithelial ovarian cancer.
June 8th 2020, 7:00pm
Konstantin Zakashansky, MD, gynecologic oncologist and associate professor of Obstetrics, Gynecology and Reproductive Science at Mount Sinai Health System, discusses repeat exposure to PARP inhibition in patients with platinum-sensitive, relapsed ovarian cancer.
May 30th 2020, 12:40am
Joyce F. Liu, MD, MPH, discusses findings from a phase 2 study with the Wee1 inhibitor adavosertib in patients with recurrent uterine serous carcinoma.
May 29th 2020, 1:00am
Gestational trophoblastic tumors (GTTs) that resist chemotherapy can be treated with frontline avelumab, making avelumab the first immunotherapy to show efficacy in treating patients with GTT, according to findings from a cohort of the ongoing phase 2 TROPHIMMUN trial.
May 29th 2020, 12:51am
Maintenance niraparib improved progression-free survival in Chinese patients with recurrent ovarian cancer who were in a complete or partial response to platinum-based chemotherapy, meeting the primary end point of the phase 3 NORA study.
May 20th 2020, 5:51pm
Brian M. Slomovitz, MD, explaines the need to determine optimal sequencing strategies in endometrial cancer.
May 20th 2020, 4:00am
May 14th 2020, 1:00am
Treatment with olaparib in the maintenance setting extended overall survival by 12.9 months in women with platinum-sensitive relapsed ovarian cancer with BRCA1/2 mutations, compared with placebo, according to randomized phase 3 trial results presented during a 2020 ASCO Virtual Scientific Program press briefing.
May 12th 2020, 2:08am
Shannon N. Westin, MD, MPH, discusses novel targets in endometrial cancer.
May 9th 2020, 6:50pm
Thomas Herzog, MD, discusses the FDA approval of olaparib plus bevacizumab for the frontline maintenance treatment of patients with homologous recombination deficiency–positive ovarian cancer.
